Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI WW FrankfurtCPhI WW Frankfurt
Not Confirmed
Not Confirmed
28-30 October, 2025
Not Confirmed
Not Confirmed
01-03 September, 2025
Not Confirmed
Not Confirmed
01-03 September, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI WW FrankfurtCPhI WW Frankfurt
Industry Trade Show
Not Confirmed
28-30 October, 2025
Industry Trade Show
Not Confirmed
01-03 September, 2025
Industry Trade Show
Not Confirmed
01-03 September, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/50-years-of-innovation-mikart-s-legacy-and-what-s-next-in-cdmo-excellence
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/fda-approvals-drop-24-in-h1-2025-gsk-s-uti-med-vertex-s-non-opioid-painkiller-lead-pack-of-first-in-class-meds
13 Aug 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/08/13/3132503/0/en/Indaptus-Therapeutics-Reports-Second-Quarter-2025-Financial-Results-and-Provides-Corporate-Update.html
01 Jul 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/07/01/3108300/0/en/Indaptus-Therapeutics-Inc-Announces-Additional-Sale-of-3-4-Million-in-Private-Placement-of-Convertible-Notes-and-Warrants.html
25 Jun 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/06/25/3104940/0/en/Indaptus-Therapeutics-Announces-Reverse-Stock-Split.html
13 Jun 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/06/13/3098973/0/en/Indaptus-Therapeutics-Inc-Announces-Sale-of-2-3-Million-in-Private-Placement-of-Convertible-Notes-and-Warrants.html
02 Jun 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/06/02/3091794/0/en/Indaptus-Therapeutics-Doses-First-Patient-in-Phase-1b-2-Combination-Study-of-Decoy20-with-PD-1-Checkpoint-Inhibitor-Tislelizumab.html
14 May 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/05/14/3081070/0/en/Indaptus-Therapeutics-Reports-First-Quarter-2025-Financial-Results-and-Provides-Corporate-Update.html
ABOUT THIS PAGE